Why the Panorama™ Prenatal Screening Test?

You and your patients deserve the reassurance that comes from having the most accurate and comprehensive genetic information available.

The Panorama prenatal test provides superior coverage and the best detection and accuracy over any other current screening methods. It provides personalized risk scores for aneuploidy at 13, 18, 21, X, Y and triploidy with the highest combined accuracy in published clinical trials among non-invasive prenatal tests currently available.

Extensive clinical coverage.

  • Identifies more chromosomal abnormalities than other non-invasive prenatal tests.

  • Includes triploidy: no other NIPT can identify triploidy

  • Calls sex chromosome trisomies when seen.

  • Its optional microdeletion panel screens for microdeletions that result in intellectual disabilities and sometimes physical disorders that are often severe.

Higher accuracy than other prenatal tests available.

A safe, convenient method that avoids invasive testing.

  • Uses a simple blood draw from the mother.

Natera’s NATUS methodology.

The Panorama prenatal test is comprehensive, accurate and provides a patient-specific personalized risk score


Identifies risk for aneuploidies of chromosomes 13, 18, 21, X and Y and triploidy

Why are sex chromosomes important?

Recent studies have demonstrated early interventions to address physical, developmental and emotional issues related to these aneuploidies can be effective. If you, your patient and her pediatrician know to look for these characteristics, they are likely to be treated much earlier, improving the quality of life for her child.1,2,3,4


The unique methodology of the Panorama prenatal test utilizes single nucleotide polymorphism (SNP) technology and is much more efficient and accurate than the counting or quantitative methods used by all other available non-invasive prenatal tests.

This NATUS (Next-generation Aneuploidy Testing Using SNPs) methodology evaluates specific genetic loci on the actual mix of maternal and fetal DNA from the mother’s blood. This allows the Panorama prenatal test to provide high sensitivity and specificity across all chromosomes, even at low fetal fractions. The result is a patient-specific individualized risk score, and better sensitivity and specificity with a decreased chance of false positives or false negatives with a low no call rate.

Comparison of Performance in Published Clinical Trials*
False Positive Rate
MaterniT21™ 1,2,3
Verifi™ 4,5
Harmony™ 6,7,8
Panorama™ *
Trisomy 21
(Down Syndrome)
>99% (83/83)
Trisomy 18
(Edwards Syndrome)
>99% (27/27)
Trisomy 13
(Patau Syndrome)
>99% (13/13)
Monosomy X
(Turner Syndrome)
91.7% (11/12)
Sex Chromosome
>99.9% 67-100% 67-100% >99% (5/5)
Female 97.9%
>99% (469/469)
Male 99.4%
>99% (533/533)
Triploidy Unable to detect Unable to detect Unable to detect >99% (8/8)

*Note: data on Panorama excludes 4 known mosaic cases: two Monosomy X, one T13, and one T18. Both cases of Monosomy X were called positive, the T18 was called negative and the T13 was no called. False positives and false negatives can occur on all chromosomes due to maternal, fetal and/or placental mosaicism or other causes.

While fetal fraction of DNA in the mother’s blood can vary greatly throughout gestational age, it does tend to be lower earlier in the pregnancy. By using SNP technology, the Panorama prenatal test has high accuracy even at lower fetal fractions and can be used as early as 9 weeks gestational age.

1 Palomaki GE et al. DNA sequencing of maternal plasma reliably identified trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;3:296-305.
2 Sequenom Internal Data (www.sequenom.com).
3 Mazloom, AR et al. Noninvasive Prenatal Detection of Sex Chromosomal Aneuploidies by Sequencing Circulating Cell-Free DNA from Maternal Plasma. Prenat Diagn 2013 June; 33(6)591-97.
4 Bianchi DW et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;5:890-901.
5 Verinata Internal Data (www.Verinata.com).
6 Ashoor G et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012 Apr; 206(4)322.31-5.
7 Ashoor G et al. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol 2-12;207:1.e1-1.e6.
8 Ariosa Internal Data (www.ariosa.com).
9 Levy, B et al. Highly multiplexed targeted single-nucleotide polymorphism (SNP) amplification and sequencing as a method for identifying fetal chromosomal disorders from maternal cell-free DNA. Presented at ESHRE July 9, 2013.
10 Nicolaides KH et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X and Y. Prenat Diagn 2013 June; 33(6): 575-579. One case of triplody identified as "triploidy or twins”.
11 Nicolaides KH et al. Maternal Fetal Medicine Foundation Congress June 2013. Four samples of diandric triploidy identified as ‘triploidy or twins’; three samples of digynic triploidy identified as having abnormally low fetal fraction (<0.5%ile), correctly raising suspicion of triploidy.
12 Samango-Sprouse C et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 2013 June; 33(7): 643-9.

Share this Page

The Panorama Advantage

  • Patient-specific personalized risk score
  • Better sensitivity and specificity
  • Decreased chance of false positives or false negatives
  • Greater detection of chromosomal abnormalities
  • Accurate even at low fetal fractions

Natera Connect

If you are a registered provider already offering Natera products, please visit our physician portal.

Natera Connect

If you wish to gain access to the portal or to get more information on the Natera family of products, contact us at info@natera.com.

Pre-NATUS Clinical Trial

Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal fetal medicine in the United States.

now recruiting patients

We are social. Follow the Panorama Test:

  Follow Natera:

You are now leaving this website. If you would like to continue, click Continue.